Comparative Review of Chronic Kidney Disease Therapeutics Coverage Across 3 Major Health Plans

How Are Health Plans Covering Chronic Kidney Disease Therapies in 2026?

Chronic kidney disease (CKD) remains a major clinical and economic challenge, with growing treatment options reshaping the standard of care. As newer therapies enter the market and payer scrutiny intensifies, understanding formulary access has become increasingly important for manufacturers, providers, and market access teams.

In this exclusive Formulary Frontlines report, we examine how three major health plans—BCBS, Cigna, and UnitedHealthcare—are covering key chronic kidney disease therapies. From formulary placement to utilization management strategies, this analysis uncovers the trends shaping patient access and payer decision-making in one of healthcare's most impactful disease states.

Key Takeaways

• Coverage approaches vary across major health plans, creating meaningful differences in access and affordability.
• Payers continue to rely on utilization management tools such as prior authorization, step therapy, and quantity limits.
• Newer CKD therapies face different levels of scrutiny and formulary positioning across plans.
• Generic-first strategies remain a key driver of formulary management.
• Evolving payer policies may have significant implications for market access and commercialization strategies.

What You'll Gain

• A side-by-side comparison of CKD formulary coverage across BCBS, Cigna, and UnitedHealthcare
• Insights into payer coverage strategies and access requirements
• Analysis of key therapeutic categories shaping CKD treatment today
• Actionable intelligence to support market access, payer engagement, and commercialization planning

As the CKD treatment landscape evolves, payer decisions will continue to influence which therapies patients can access—and under what conditions.

Download the full report to explore the latest formulary trends and coverage strategies shaping chronic kidney disease care.